Medications for Autism Spectrum Disorder
Pharmacotherapy in autism spectrum disorder (ASD) should be reserved for specific target symptoms or comorbid conditions, not for core social-communication deficits, with risperidone and aripiprazole being the only FDA-approved medications—specifically for treating severe irritability, aggression, and tantrums. 1
Core Principle: Symptom-Targeted Treatment
There are no medications that treat the core features of autism (social communication deficits, restricted interests). Medications are used exclusively to manage:
- Severe behavioral symptoms (irritability, aggression, self-injury, tantrums)
- Comorbid psychiatric conditions (ADHD, anxiety, depression, OCD)
- Associated features (sleep disturbances, hyperactivity, repetitive behaviors)
FDA-Approved Medications (First-Line for Severe Irritability)
Atypical Antipsychotics
Risperidone and aripiprazole are the only FDA-approved medications for ASD, indicated specifically for irritability consisting of physical aggression and severe tantrum behavior. 1
- Risperidone: Demonstrated approximately -11.0 point reduction on the Aberrant Behavior Checklist-Irritability subscale across pooled trials 3
- Aripiprazole: Similar efficacy but with a more favorable metabolic profile (less weight gain than risperidone) 3
Common side effects: Sedation, increased appetite, weight gain, metabolic changes, and extrapyramidal symptoms 1
Critical caveat: These medications carry significant metabolic burden. Risperidone has greater weight gain risk than aripiprazole. 3 Patients on atypical antipsychotics switch medications nearly twice as often as those on SSRIs (6.13% vs 3.41% annually), likely due to adverse effects or insufficient response. 4
Medications for Comorbid ADHD Symptoms
When hyperactivity, inattention, and impulsivity are prominent:
- Methylphenidate: 49% response rate in children with ASD and elevated hyperactivity scores 1
- Atomoxetine, clonidine, guanfacine: Alternative options for ADHD symptoms 2, 5
Note: The DSM-5 removed the historical prohibition against diagnosing ADHD in patients with ASD, making stimulant treatment appropriate when indicated. 1
Medications for Anxiety, Depression, and Repetitive Behaviors
SSRIs: Limited Evidence
SSRIs are NOT recommended for repetitive behaviors in youth with ASD. Two double-blind, placebo-controlled studies provide evidence against their use for this indication. 6
However, SSRIs may be considered off-label for:
SNRIs: Variable Evidence
- Venlafaxine: Useful as adjuvant for self-injurious behaviors, aggression, and ADHD symptoms at doses lower than typical antidepressant dosing 7
- Duloxetine: No demonstrated benefit 7
- Milnacipran: May improve impulsivity, hyperactivity, and social functioning through reduction of inattention 7
Sleep Disturbances
Melatonin is the medication of choice for sleep disturbances in ASD. 2, 5
Emerging and Investigational Therapies (Not Yet Standard of Care)
The following show preliminary evidence but lack robust support for routine use:
- Oxytocin and vasopressin: No consistent benefit for social impairment demonstrated 6
- Memantine: Inconsistent results for social deficits 6
- Cannabidiol (CBD): Preliminary studies for irritability, but safety and efficacy not established 6
- Folinic acid: Three RCTs show preliminary evidence for verbal language deficits in children with ASD 6; high-dose folinic acid efficacy concentrated in subgroup with folate receptor-α autoantibodies 3
- Microbiota transfer therapy: Significant improvement in GI and behavioral symptoms in cohorts with GI disease 3
Critical Clinical Algorithm
Step 1: Identify the specific target symptom or comorbidity
- Severe irritability/aggression/tantrums → Risperidone or aripiprazole
- ADHD symptoms → Methylphenidate, atomoxetine, or alpha-2 agonists
- Anxiety/depression → Consider SSRIs (off-label)
- Sleep disturbances → Melatonin
Step 2: Combine medication with parent training when treating behavioral disturbances
- Medication + parent training is moderately more efficacious than medication alone for behavioral problems and modestly better for adaptive functioning 1
Step 3: Monitor with objective rating scales
- Use Aberrant Behavior Checklist (ABC), Clinical Global Impression (CGI), or other validated tools
- Treatment response often judged by caregiver report, especially in nonverbal patients 1
Step 4: Remember the ultimate goal
- Facilitate the child's adjustment and engagement with educational interventions
- Enable the child to remain in less restrictive environments 1
Common Pitfalls to Avoid
- Do not use medications to treat core ASD symptoms (social communication deficits)—no medication is effective for this purpose
- Do not prescribe SSRIs for repetitive behaviors—evidence shows they are ineffective 6
- Monitor metabolic side effects closely with atypical antipsychotics, particularly weight gain and metabolic syndrome
- Avoid diagnostic overshadowing—actively screen for and treat comorbid conditions (anxiety, depression, ADHD) that may be masked by the ASD diagnosis 1
- Do not use medication as monotherapy for behavioral disturbances—combine with parent training for optimal outcomes 1
The Future: Precision Medicine Approach
Current evidence demands a shift toward precision medicine. Treatment efficacy is highly variable and concentrated in specific patient subgroups (e.g., folate receptor-α autoantibodies for folinic acid, GI disease for microbiota therapy). 3 Future practice will require validation of biological biomarkers (metabolic, genetic, neurophysiological) to predict treatment response and guide targeted therapy selection. 3, 5